ES2557988T3 - Método para tratar enfermedades de próstata basado en el suministro local de principios activos - Google Patents
Método para tratar enfermedades de próstata basado en el suministro local de principios activos Download PDFInfo
- Publication number
- ES2557988T3 ES2557988T3 ES06724133.1T ES06724133T ES2557988T3 ES 2557988 T3 ES2557988 T3 ES 2557988T3 ES 06724133 T ES06724133 T ES 06724133T ES 2557988 T3 ES2557988 T3 ES 2557988T3
- Authority
- ES
- Spain
- Prior art keywords
- active ingredients
- diseases based
- local supply
- treat prostate
- prostate diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un kit que comprende i) un primer componente que proporciona una dosis de refuerzo inicial de uno o más principios activos y/o profármacos seleccionados de fármacos antiandrógenos y/o un agente citostático; y ii) un segundo componente que comprende una composición farmacéutica de liberación controlada que comprende uno o más principios activos seleccionados de fármacos antiandrógenos y/o un agente citostático, en un vehículo cerámico biodegradable seleccionado de sulfato cálcico, para el tratamiento de enfermedades relacionadas con la próstata.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500452 | 2005-03-31 | ||
DK200500452 | 2005-03-31 | ||
PCT/EP2006/003194 WO2006103112A2 (en) | 2005-03-31 | 2006-03-31 | Method for treating prostate diseases based on local delivery of active substances |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2557988T3 true ES2557988T3 (es) | 2016-02-01 |
Family
ID=35044589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES06724133.1T Active ES2557988T3 (es) | 2005-03-31 | 2006-03-31 | Método para tratar enfermedades de próstata basado en el suministro local de principios activos |
Country Status (17)
Country | Link |
---|---|
US (1) | US8936809B2 (es) |
EP (1) | EP1865924B1 (es) |
JP (2) | JP5635231B2 (es) |
KR (2) | KR20140014294A (es) |
CN (1) | CN101160116B (es) |
AU (1) | AU2006228675B2 (es) |
CA (1) | CA2602776C (es) |
DK (1) | DK1865924T3 (es) |
ES (1) | ES2557988T3 (es) |
HU (1) | HUE026158T2 (es) |
IL (1) | IL185690A0 (es) |
MX (1) | MX2007011908A (es) |
NO (1) | NO338679B1 (es) |
PL (1) | PL1865924T3 (es) |
RU (1) | RU2404747C2 (es) |
WO (1) | WO2006103112A2 (es) |
ZA (1) | ZA200708066B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8936809B2 (en) * | 2005-03-31 | 2015-01-20 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
WO2010060644A1 (en) * | 2008-11-27 | 2010-06-03 | Lidds Ab | Use of carboxymethylcellulose to control ejectability and solidification of time of compositions one or more bioresorbable ceramics |
JP6336899B2 (ja) * | 2011-04-05 | 2018-06-06 | エッジ セラピューティクス インコーポレイテッド | 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム |
RU2519407C2 (ru) * | 2011-09-21 | 2014-06-10 | Виктор Павлович Горелов | Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты |
GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
US10912933B2 (en) * | 2014-08-19 | 2021-02-09 | The Regents Of The University Of California | Implants for localized drug delivery and methods of use thereof |
CN107683131B (zh) | 2015-06-04 | 2021-09-28 | 克里蒂泰克公司 | 紫杉烷颗粒及其用途 |
ES2858092T3 (es) | 2016-04-04 | 2021-09-29 | Crititech Inc | Formulaciones para el tratamiento de tumores sólidos |
BR112019023948A2 (pt) | 2017-06-09 | 2020-06-09 | Crititech Inc | tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas |
CN110799176A (zh) | 2017-06-14 | 2020-02-14 | 克里蒂泰克公司 | 治疗肺部疾病的方法 |
RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
US11173291B2 (en) * | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
US11344526B2 (en) * | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
CA3171976A1 (en) * | 2020-03-20 | 2021-09-23 | Carlos Schuler | Implantable drug delivery devices for localized drug delivery |
US11338119B2 (en) * | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
WO2023147080A1 (en) * | 2022-01-29 | 2023-08-03 | Resurge Therapeutics, Inc. | Benign prostatic hyperplasia treatment system |
US11974979B2 (en) | 2022-01-29 | 2024-05-07 | Resurge Therapeutics, Inc. | Treatments for benign prostatic hyperplasia |
US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
US5795330A (en) * | 1996-10-10 | 1998-08-18 | Etex Corporation | Mixing device |
US6972130B1 (en) * | 1996-10-16 | 2005-12-06 | Etex Corporation | Bioceramic compositions |
US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
US5972384A (en) * | 1997-10-01 | 1999-10-26 | University Of Maryland, Baltimore | Use of biologically active glass as a drug delivery system |
EP1208850A1 (en) | 1999-08-05 | 2002-05-29 | Takeda Chemical Industries, Ltd. | Pastes with the sustained release of osteogenesis promoter |
US6497901B1 (en) * | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
US6645974B2 (en) * | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
US20030147936A1 (en) * | 2002-02-07 | 2003-08-07 | Velayudhan Sahadevan | Prostatic hormonal implants treatment of prostate cancer |
AU2004223866A1 (en) * | 2003-03-24 | 2004-10-07 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
GB0307082D0 (en) | 2003-03-27 | 2003-04-30 | Gyne Ideas Ltd | Drug delivery device and method |
EP1608359A4 (en) * | 2003-04-03 | 2011-08-17 | Jessie L-S Au | DRUG-LOADING PARTICLES TARGETING TUMORS |
US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
WO2005039537A1 (en) * | 2003-10-22 | 2005-05-06 | Lidds Ab | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
US8936809B2 (en) * | 2005-03-31 | 2015-01-20 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
-
2006
- 2006-03-31 US US11/910,162 patent/US8936809B2/en active Active
- 2006-03-31 AU AU2006228675A patent/AU2006228675B2/en active Active
- 2006-03-31 RU RU2007140243/14A patent/RU2404747C2/ru active
- 2006-03-31 MX MX2007011908A patent/MX2007011908A/es active IP Right Grant
- 2006-03-31 HU HUE06724133A patent/HUE026158T2/en unknown
- 2006-03-31 DK DK06724133.1T patent/DK1865924T3/en active
- 2006-03-31 KR KR1020137034233A patent/KR20140014294A/ko not_active Application Discontinuation
- 2006-03-31 PL PL06724133T patent/PL1865924T3/pl unknown
- 2006-03-31 CN CN2006800100200A patent/CN101160116B/zh active Active
- 2006-03-31 CA CA2602776A patent/CA2602776C/en active Active
- 2006-03-31 EP EP06724133.1A patent/EP1865924B1/en active Active
- 2006-03-31 KR KR1020077022037A patent/KR101380402B1/ko active IP Right Grant
- 2006-03-31 JP JP2008503447A patent/JP5635231B2/ja active Active
- 2006-03-31 WO PCT/EP2006/003194 patent/WO2006103112A2/en active Application Filing
- 2006-03-31 ES ES06724133.1T patent/ES2557988T3/es active Active
-
2007
- 2007-09-03 IL IL185690A patent/IL185690A0/en active IP Right Grant
- 2007-09-19 ZA ZA2007/08066A patent/ZA200708066B/en unknown
- 2007-10-30 NO NO20075490A patent/NO338679B1/no unknown
-
2012
- 2012-11-27 JP JP2012258603A patent/JP2013067639A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP1865924B1 (en) | 2015-12-09 |
HUE026158T2 (en) | 2016-05-30 |
DK1865924T3 (en) | 2016-02-29 |
WO2006103112A2 (en) | 2006-10-05 |
US20080286205A1 (en) | 2008-11-20 |
MX2007011908A (es) | 2008-02-07 |
IL185690A0 (en) | 2008-01-06 |
RU2007140243A (ru) | 2009-05-10 |
NO338679B1 (no) | 2016-09-26 |
AU2006228675B2 (en) | 2012-05-17 |
US8936809B2 (en) | 2015-01-20 |
PL1865924T3 (pl) | 2016-06-30 |
JP5635231B2 (ja) | 2014-12-03 |
CN101160116A (zh) | 2008-04-09 |
KR20140014294A (ko) | 2014-02-05 |
NO20075490L (no) | 2008-01-02 |
ZA200708066B (en) | 2016-07-27 |
KR101380402B1 (ko) | 2014-04-02 |
KR20080002776A (ko) | 2008-01-04 |
CA2602776A1 (en) | 2006-10-05 |
EP1865924A2 (en) | 2007-12-19 |
AU2006228675A1 (en) | 2006-10-05 |
JP2013067639A (ja) | 2013-04-18 |
CA2602776C (en) | 2013-10-22 |
JP2008534546A (ja) | 2008-08-28 |
CN101160116B (zh) | 2011-12-07 |
WO2006103112A3 (en) | 2006-12-21 |
RU2404747C2 (ru) | 2010-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2557988T3 (es) | Método para tratar enfermedades de próstata basado en el suministro local de principios activos | |
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
ES2497494T3 (es) | Método de tratamiento y prevención del hiperparatiroidismo secundario | |
ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
CL2011000916A1 (es) | Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer. | |
BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
CL2008002224A1 (es) | Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer. | |
BR0316310A (pt) | Composições farmacêuticas tendo um veìculo modificado | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
AR055319A1 (es) | Derivados de isoquinoleina, composiciones farmaceuticas y usos | |
UY29274A1 (es) | Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida | |
BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
CL2008003699A1 (es) | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. | |
CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. | |
PE20040990A1 (es) | Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos | |
AR056749A1 (es) | Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso | |
CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
BRPI0418070A (pt) | composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais | |
CL2007002878A1 (es) | Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer. | |
ECSP066649A (es) | Preparado efervescente de una sustancia básica farmacéuticamente activa |